Clinical and ultrastructural effects of acitretin in Darier's disease.
Jorma Lauharantaa, Lasse Kanerva, Kristiina Turjanmaa, Geiger Jm
- aDepartment of Dermatology, University Central Hospital, Helsinki, Finland
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Thirteen patients with Darier's disease with a mean extent of the lesions of 29.4 +/- 10% of the total skin area were treated with acitretin (the main metabolite of etretinate) for 16 weeks. The dose was 30 mg/day during the initial 8 weeks and was later adjusted individually to 10-30 mg/day in order to achieve optimal results. Three patients cleared completely, 7 patients showed marked improvement and 3 patients became slightly better during treatment. The mean extent of the lesions after the treatment was 7.3 +/- 8% of the skin area. Despite good clinical clearing, the improvement at the ultrastructural level was incomplete in the 3 patients studied by electron microscopy. Normal stratification did not develop and the size and number of desmosomes remained reduced. The main side effects during treatment were pruritus in 5 patients, diffuse alopecia in 2 patients and marked elevation in serum triglycerides in 4 patients. On the basis of this study, acitretin would seem to be a useful alternative to etretinate for the treatment of Darier's disease.
TL;DRThirteen patients with Darier's disease with a mean extent of the lesions of 29.4 +/- 10% of the total skin area were treated with acitretin for 16 weeks and it would seem to be a useful alternative to etretinate for the treatment of Dariers disease. (Semantic Scholar)